D-Mannose
Naturally occurring C-2 epimer of glucose used as a urinary-health supplement. After oral dosing, blood concentrations peak in about one to two hours and decline with an approximately four-hour half-time. Urinary mannose can bind mannose-sensitive FimH adhesins in some uropathogenic Escherichia coli, but this mechanism does not establish clinical benefit. The largest placebo-controlled primary-care trial found that 2 g/day did not prevent recurrent urinary tract infection.
Projected serum levels — 2k mg, once daily
Maintenance schedule: 2k mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 1.3k mg, trough ≈ 33.0 mg body load. Population-based estimate over 15 days for a 2k mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Urinary Health
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 4 h
- Common dose
- 2k mg
- Suggested maximum
- 14.7k mg/day
- Reference dose range
- 500–14.7k mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Oral ingestion of mannose elevates blood mannose levels - a first step toward a potential therapy for carbohydrate-deficient glycoprotein syndrome type I
Human dose-ranging study found efficient oral uptake, dose-dependent blood exposure, one-to-two-hour peaks, and an approximately four-hour clearance half-time after 0.07-0.21 g/kg. It established systemic kinetics in a…
-
Role of D-mannose in urinary tract infections - a narrative review
Industry-authored narrative review explains FimH-mediated bacterial adhesion and summarizes early clinical studies. It describes biological plausibility but predates the largest placebo-controlled trial and cannot…
-
D-mannose for preventing and treating urinary tract infections
Cochrane review included seven heterogeneous randomized trials with 719 participants. Studies could not be pooled; risk of bias was generally unclear or high, outcomes were sparse, and certainty was very low. The…
-
Nonantibiotic prevention and management of recurrent urinary tract infection
Broad narrative review covers D-mannose among many nonantibiotic strategies and concluded that promising early approaches still required high-level evidence before firm recommendations. It is contextual evidence rather…
6 published studies referenced in the app, each with a plain-language summary.